{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:11:37Z","timestamp":1778749897912,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.prp.2026.156509","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:58:33Z","timestamp":1777701513000},"page":"156509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PTEN-low associated mismatch repair deficiency and nuclear PD-L1 expression in basal-type bladder cancer"],"prefix":"10.1016","volume":"283","author":[{"given":"Qiaoli","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enyi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2026.156509_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA a Cancer J. Clin."},{"key":"10.1016\/j.prp.2026.156509_bib2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.prp.2026.156509_bib3","first-page":"203","article-title":"Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"10.1016\/j.prp.2026.156509_bib4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2018.08.027","article-title":"Molecular subtypes of urothelial bladder cancer: results from a meta-cohort analysis of 2411 tumors","volume":"75","author":"Tan","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.prp.2026.156509_bib5","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ajpath.2013.05.013","article-title":"Toward a molecular pathologic classification of urothelial carcinoma","volume":"183","author":"Sj\u00f6dahl","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.prp.2026.156509_bib6","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"Molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.prp.2026.156509_bib7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/ncb3038","article-title":"Bladder cancers arise from distinct urothelial sub-populations","volume":"16","author":"Van Batavia","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.prp.2026.156509_bib8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.prp.2026.156509_bib9","doi-asserted-by":"crossref","first-page":"244ra291","DOI":"10.1126\/scitranslmed.3008970","article-title":"EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype","volume":"6","author":"Rebouissou","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.prp.2026.156509_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215924","article-title":"Structural or functional defects of PTEN in urothelial cells lacking P53 drive basal\/squamous-subtype muscle-invasive bladder cancer","volume":"550","author":"He","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2026.156509_bib11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nature14034","article-title":"Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance","volume":"517","author":"Kurtova","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156509_bib12","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/his.13696","article-title":"Basal-subtype bladder tumours show a 'hot' immunophenotype","volume":"73","author":"Hodgson","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2026.156509_bib13","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet (Lond. Engl. )"},{"key":"10.1016\/j.prp.2026.156509_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.527385","article-title":"PD-L1 expression in muscle-invasive urinary bladder urothelial carcinoma according to basal\/squamous-like phenotype","volume":"10","author":"Kim","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156509_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","article-title":"Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use","volume":"12","author":"Dadhania","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.prp.2026.156509_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076610","article-title":"Clinicopathological features and survival analysis in molecular subtypes of muscle-invasive bladder cancer","volume":"24","author":"Sanguedolce","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156509_bib17","article-title":"Molecular subtyping and immunohistochemistry validation identifies muscle Invasive bladder cancer subgroups with poorer overall survival","volume":"84","author":"Zhang","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2026.156509_bib18","article-title":"Unlocking breast cancer in Brazilian public health system: using tissue microarray for accurate immunohistochemical evaluation with limitations in subtyping","volume":"21","author":"Ruppenthal","year":"2025","journal-title":"Women\u2019s. Health"},{"key":"10.1016\/j.prp.2026.156509_bib19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1158\/1078-0432.CCR-16-0680","article-title":"Practical and robust identification of molecular subtypes in colorectal cancer by immunohistochemistry","volume":"23","author":"Trinh","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.prp.2026.156509_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238836","article-title":"Protein expression-based classification of gastric cancer by immunohistochemistry of tissue microarray","volume":"15","author":"Zhao","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.prp.2026.156509_bib21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.prp.2026.156509_bib22","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/his.13225","article-title":"p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant","volume":"71","author":"Hodgson","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2026.156509_bib23","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.csbj.2021.01.022","article-title":"QuPath: the global impact of an open source digital pathology system","volume":"19","author":"Humphries","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.prp.2026.156509_bib24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.eursup.2017.09.004","article-title":"Variants of bladder cancer: the pathologist's point of view","volume":"16","author":"Lopez-Beltran","year":"2017","journal-title":"Eur. Urol. Suppl."},{"key":"10.1016\/j.prp.2026.156509_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2026.156509_bib26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00345-015-1615-3","article-title":"The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer","volume":"34","author":"Horn","year":"2016","journal-title":"World J. Urol."},{"key":"10.1016\/j.prp.2026.156509_bib27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12967-023-03949-3","article-title":"Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis","volume":"21","author":"Koll","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.prp.2026.156509_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12061360","article-title":"Modified immunoscore improves prediction of survival outcomes in patients undergoing radical cystectomy for bladder cancer-a retrospective digital pathology study","volume":"12","author":"Bieri","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.prp.2026.156509_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.964672","article-title":"Modified immunoscore improves the prediction of progression-free survival in patients with non-muscle-invasive bladder cancer: a digital pathology study","volume":"12","author":"Bieri","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156509_bib30","doi-asserted-by":"crossref","first-page":"63.e19","DOI":"10.1016\/j.urolonc.2021.07.025","article-title":"Utility of stromal tumor infiltrating lymphocyte scoring (sTILs) for risk stratification of patients with muscle-invasive urothelial bladder cancer after radical cystectomy","volume":"40","author":"Sikic","year":"2022","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.prp.2026.156509_bib31","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-768","article-title":"Immunohistochemistry analysis of the molecular subtypes of muscle invasive bladder cancer in association with prognosis","volume":"83","author":"Pham","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2026.156509_bib32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s43046-025-00279-x","article-title":"Microsatellite instability and mismatch repair deficiency in bladder urothelial carcinoma: a Tunisian single-center study","volume":"37","author":"Bdioui","year":"2025","journal-title":"J. Egypt Natl. Cancer Inst."},{"key":"10.1016\/j.prp.2026.156509_bib33","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2026.156509_bib34","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/jclinpath-2019-206256","article-title":"Correlation of mismatch repair protein deficiency, PD-L1 and CD8 expression in high-grade urothelial carcinoma of the bladder","volume":"73","author":"Hodgson","year":"2020","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.prp.2026.156509_bib35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/jamaoncol.2017.4182","article-title":"Cancer drugs approved based on biomarkers and not tumor type-FDA approval of pembrolizumab for mismatch repair-deficient solid cancers","volume":"4","author":"Prasad","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.prp.2026.156509_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041461","article-title":"PTEN expression as a complementary biomarker for mismatch repair testing in breast cancer","volume":"21","author":"Lopez","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156509_bib37","article-title":"Retained PTEN expression preferentially identifies mismatch repair-proficient breast cancers","volume":"1","author":"Fusco","year":"2016","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.prp.2026.156509_bib38","first-page":"1401","article-title":"Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas","volume":"26","author":"Djordjevic","year":"2013","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc."},{"key":"10.1016\/j.prp.2026.156509_bib39","first-page":"237","article-title":"Nuclear localization of PD-L1: artifact or reality?","volume":"42","author":"Polioudaki","year":"2019","journal-title":"Cell. Oncol. (Dordr. Neth. )"},{"key":"10.1016\/j.prp.2026.156509_bib40","doi-asserted-by":"crossref","first-page":"28910","DOI":"10.1038\/srep28910","article-title":"Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients","volume":"6","author":"Satelli","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2026.156509_bib41","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2605","article-title":"Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule","volume":"12","author":"Ghebeh","year":"2010","journal-title":"Breast cancer research BCR"},{"key":"10.1016\/j.prp.2026.156509_bib42","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41556-020-0562-4","article-title":"Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy","volume":"22","author":"Gao","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.prp.2026.156509_bib43","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s41418-020-00651-5","article-title":"KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6\/MerTK signaling pathway","volume":"28","author":"Du","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.prp.2026.156509_bib44","article-title":"Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations","volume":"216","author":"Hodgson","year":"2020","journal-title":"Pathol. Res Pr."},{"key":"10.1016\/j.prp.2026.156509_bib45","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13000-022-01273-w","article-title":"p53 immunostaining pattern is a useful surrogate marker for TP53 gene mutations","volume":"17","author":"Sung","year":"2022","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.prp.2026.156509_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/gcc.23271","article-title":"17p13 (TP53) deletions are associated with an aggressive phenotype but unrelated to patient prognosis in urothelial bladder carcinomas","volume":"63","author":"Kluth","year":"2024","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.prp.2026.156509_bib47","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1186\/1756-0500-5-466","article-title":"Specific-mutational patterns of p53 gene in bladder transitional cell carcinoma among a group of Iraqi patients exposed to war environmental hazards","volume":"5","author":"Al-Kashwan","year":"2012","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.prp.2026.156509_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202500241","article-title":"Identification of multi-landscape and cell interactions in the tumor microenvironment through high-coverage single-cell sequencing","volume":"9","author":"Zhong","year":"2025","journal-title":"Small Methods"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826001627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826001627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:28:35Z","timestamp":1778747315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826001627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":48,"alternative-id":["S0344033826001627"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156509","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PTEN-low associated mismatch repair deficiency and nuclear PD-L1 expression in basal-type bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156509","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156509"}}